StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
4172.T$2220.00-0.67%
Fair $2220.00+0.0%

4172.T

Hi-CRATES CO.,LTD.

Healthcare / Health Information ServicesTokyo

$2220.00

-15.00 (-0.67%)

Fairly Valued+0.0%Fair Value $2220.00Fund rank 27/100 · Data gapFallback financials|
SA 37/D
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 21%

FCF escenarios

weak_data · normalized FCF $418.2M · quality 41.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 40/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 4172.TLocal privado en este navegador · Hi-CRATES CO.,LTD.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4.9B

P/E

10.9x

↓

EV/EBITDA

5.4x

↓

ROE

10.7%

↑

Gross Margin

77.0%

↑

Debt/Equity

N/A

•
52-Week Range$2220
$2106$2549

TradingView lightweight chart

4172.T price, volumen y niveles de valoración

Último $2,220Periodo -48.4%
Fair value: $2,220

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.8%

FCF CAGR

+19.7%

FCF margin

17.4%

FCF / Net income

0.93x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.41B · net income $448.1M · FCF $418.2M

2022-FY → 2025-FY

Gross margin

77.0%+3.5% pts

Operating margin

22.8%+4.0% pts

Net margin

18.6%+4.3% pts

FCF margin

17.4%+6.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.41B$2.41B$2.11B$2.04B$2.22B
Net Income$448.1M$448.1M$401.8M$258.5M$316.3M
EBITDA$638.0M$638.0M$500.8M$299.3M$465.2M
EPS201.13201.13180.35116.03141.96
Gross Margin77.0%77.0%75.8%71.6%73.5%
Operating Margin22.8%22.8%20.0%11.3%18.8%
Net Margin18.6%18.6%19.0%12.7%14.3%
Balance Sheet
Current Ratio5.875.87———
Cash Flow
Free Cash Flow$418.2M$418.2M$490.6M$-115.8M$243.9M
Returns
ROE10.7%10.7%10.2%6.9%8.8%
Valuation
P/E10.9410.9410.6014.6012.98
EV/EBITDA5.415.415.307.924.96
P/B1.181.181.081.011.14
Growth & Yield
Revenue Growth13.9%13.9%3.5%-7.8%—
EPS Growth11.5%11.5%55.4%-18.3%—
Dividend Yield4.0%4.0%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-0.7%

fácil

EPS terminal req.

$196.99

Spread vs growth

12.2%

5Y implied EPS CAGR

3.5%

fácil

EPS terminal req.

$238.36

Spread vs growth

8.1%

10Y implied EPS CAGR

6.7%

razonable

EPS terminal req.

$383.87

Spread vs growth

4.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +9.4%

Total return

+9.4%

Start / end P/E

11.7x → 11.0x

EPS bridge

180.35 → 201.13

Residual

-0.6%

EPS growth+11.5%
Multiple rerating-5.5%
Dividend+4.0%
Residual / FX / buybacks / cross-term-0.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.